Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.68 |
| ▸ | AR | P10275 | 11/20 | 0.64 |
| ▸ | PARP1 | P09874 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404780 | 1.00 | PRMT5 (0.68) | PRMT5ARPARP1LMNAPOLB | |
| SCHEMBL6366635 | 0.81 | PRMT5 (0.58) | PRMT5ARPARP1LMNAPOLB | |
| SCHEMBL30231202 | 0.81 | PRMT5 (0.68) | PRMT5ARPARP1LMNAPOLB | |
| SCHEMBL21575704 | 0.81 | PRMT5 (0.68) | PRMT5ARPARP1LMNAPOLB | |
| SCHEMBL7462930 | 0.81 | PRMT5 (0.68) | PRMT5ARPARP1LMNAPOLB | |
| SCHEMBL6328127 | 0.81 | PRMT5 (0.68) | PRMT5ARPARP1LMNAPOLB | |
| SCHEMBL4713938 | 0.81 | PRMT5 (1.00) | PRMT5ARPARP1LMNAPOLB | |
| SCHEMBL31057993 | 0.81 | PRMT5 (1.00) | PRMT5ARPARP1LMNAPOLB | |
| SCHEMBL4817305 | 0.81 | PRMT5 (0.68) | PRMT5ARPARP1LMNAPOLB | |
| SCHEMBL6374999 | 0.80 | PARP1 (0.59) | PRMT5ARPARP1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022036940-A1 | PREPARATION METHOD FOR FLUZOPARIB | 苏州富士莱医药股份有限公司 | 2022-02-24 | — | — | WO | claimed |
| CN-113234024-A | Novel preparation method of olapari | 北京迈索化学技术有限公司 | 2021-08-10 | — | — | CN | claimed |
| CN-111732594-B | Preparation method of fluxaparide | 苏州富士莱医药股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-111732594-B | Preparation method of fluxaparide | 苏州富士莱医药股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2022036940-A1 | PREPARATION METHOD FOR FLUZOPARIB | 苏州富士莱医药股份有限公司 | 2022-02-24 | — | — | WO | disclosed |
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| CN-113234024-A | Novel preparation method of olapari | 北京迈索化学技术有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-113234024-A | Novel preparation method of olapari | 北京迈索化学技术有限公司 | 2021-08-10 | — | — | CN | disclosed |
| CN-111732594-A | Preparation method of fluxaparide | 苏州富士莱医药股份有限公司 | 2020-10-02 | — | — | CN | disclosed |
| CN-111732594-A | Preparation method of fluxaparide | 苏州富士莱医药股份有限公司 | 2020-10-02 | — | — | CN | disclosed |
| CN-110869359-A | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | 加拉帕戈斯股份有限公司 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | PRMT5 3849/4885AR 890/4885PARP1 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.